ORMP Latest Report

Performance Review

In analyzing Oramed's (Symbol: ORMP) total operating revenue as of December 31, 2024, we note that the Company's operating revenue in its 2024 financial statement was -35.95 million yuan, an improvement from -38.77 million yuan in the same period of 2023. This change indicates that Oramed's operating revenue has increased year-on-year in 2024, albeit still in the negative territory.

Key Financial Data

1. As of December 31, 2024, Oramed's operating revenue was -35.95 million yuan, an improvement of 2.82 million yuan from -38.77 million yuan as of December 31, 2023, indicating potential recovery in revenue.

2. Although operating revenue remains negative, the improvement suggests that the Company's efforts in revenue may be bearing fruit.

3. The improvement in operating revenue may be attributed to changes in market demand, operational efficiency, cost control, and new product launches, among others.

Peer Comparison

1. Industry-wide analysis: In the biopharmaceutical industry, the overall market environment may be affected by the progress of new drug development and policy support, leading to fluctuations in operating revenue among industry companies. For Oramed, the overall recovery in the industry may provide better market opportunities.

2. Peer evaluation analysis: Compared with other companies in the same industry, although Oramed's operating revenue improvement is still negative, if other companies' operating revenues are also declining, Oramed's improvement may demonstrate its relative resilience in the industry.

Summary

Oramed's operating revenue improved in 2024, albeit still in the negative zone. This change implies that the Company's efforts in boosting revenue have achieved some results, but the market demand and operational efficiency still need to be continuously improved.

Opportunities

1. The future recovery in market demand may further drive revenue growth.

2. If the Company can continuously optimize operational efficiency, it may further improve operating revenue.

3. Potential policy support will create a better development environment for the biopharmaceutical industry, and Oramed can take advantage of this opportunity to enhance its market share.

Risks

1. Oramed may fail to successfully launch new products in 2024, which will continue to put pressure on revenue.

2. Intensified competition within the industry may lead to price wars, affecting operating revenue.

3. If market demand fails to recover, the Company may still face the risk of declining revenue.